75 Sandy Pond Road Ayer
15 articles with Alcyone Lifesciences
Alcyone Lifesciences Announces Broad Strategic Collaboration with Roche in the Field of Intrathecal Therapies
Collaboration leverages strengths to advance the progress of intrathecal therapies to treat severe neurological conditions
Alcyone Lifesciences Announces the Use of AMC Intratumoral Delivery Platform in the Treatment of First Patient in DNX-2440 Glioblastoma Trial
Alcyone Lifesciences, a leader in breakthrough technologies to treat complex oncolytic and neurological conditions through the company's proprietary advanced precision delivery platform, announced that the first patient was treated with DNAtrix's DNX-2440, an oncolytic adenovirus expressing OX40 ligand (OX40L) in a Phase 1 clinical trial for recurrent glioblastoma multiforme (GBM), a particularly lethal form of brain cancer.
Promising Treatment of Challenging Pediatric Brain Stem Tumor, DIPG, with Alcyone AMC Precision Delivery of Oncolytic Adenovirus
Alcyone Lifesciences, Inc. announced encouraging progress by investigators at the Clínica Universidad de Navarra regarding the Alcyone MEMS Cannula (AMC) precision delivery of an oncolytic adenovirus in a small series of patients with a pediatric brain stem tumor, diffuse intrinsic pontine glioma (DIPG).
Alcyone Lifesciences Announces Presentation on Intrathecal Physical Methods of Delivery of Gene Therapeutics at 2018 American Society of Cell and Gene Therapy Conference
Alcyone Lifesciences, Inc., a leader in disease modifying therapies for the central nervous system (CNS) through its Advanced Precision Delivery Platforms, announced a presentation on its intrathecal delivery technology platform that has the potential to impact several CNS gene therapies and their development.
Alcyone Lifesciences Announces Research Collaboration With a Leading Biopharmaceutical Company to Improve Intrathecal Delivery of Therapies for Rare and Orphan Neurological Conditions
Alcyone's proprietary Pulsar advanced precision CNS delivery platform utilizes the cerebrospinal fluid dynamics to precision deliver and optimally biodistribute therapeutics to targets of interest in the CNS.
11/15/2017This comes on the heels of Alcyone receiving the EU CE Mark last month.
Alcyone Lifesciences Enters Into A Feasibility Study Agreement With Pfizer To Evaluate Alcyone's Proprietary Pulsar Advanced Intrathecal Precision Delivery Platform Technology For Use In Gene Therapy Targeting Central Nervous System Disorders
Alcyone Lifesciences Announces Allowance Of First Patent Related To ReFlow System For The Treatment Of Hydrocephalus
Lysogene And Alcyone Lifesciences Enter Into A Collaboration For Mucopolysaccharidosis Type IIIA (MPS IIIA)
Dr. Olivier Danos, Cell And Gene Therapy Pioneer, Joins Alcyone Lifesciences Scientific Advisory Board
Alcyone Lifesciences Appoints Michael Rogawski, International Expert In Treatment Of Seizures And Epilepsy To Its Clinical And Scientific Advisory Board